Colorectal Cancer Clinical Trials
Colorectal cancer clinical trials are valuable tools that allow patients to benefit from new treatments as soon as they become available. At the same time, these important research studies help scientists and physicians improve the standard of care. During a trial, if a new treatment is found to be more effective than the currently available options, that treatment may become the new standard. In fact, all of today’s standard treatments were chosen based on the results of past clinical trials.
Patients who participate in colorectal cancer clinical trials at Moffitt Cancer Center can feel confident that they will:
- Receive the best possible treatment to meet their individual needs in the form of either newly discovered therapies or the current standard of care
- Be evaluated and monitored by a multispecialty team of cancer experts who will adhere to a carefully designed testing protocol and make highly individualized, evidence-based recommendations
- Benefit other colorectal cancer patients by helping to improve the standard of care
Through our ongoing research efforts and robust portfolio of clinical trials, Moffitt is achieving better cancer outcomes and providing our patients with higher-quality lives. We are also continually moving forward by identifying causes, developing prevention strategies and discovering new and better treatments for colorectal cancer. As a result of this commitment, Moffitt has earned the distinction of being the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, a prestigious designation that is nationally recognized by medical professionals and patients alike. Thousands of patients come to Moffitt for innovative treatments and compassionate care.
If you’d like to learn more about the current colorectal cancer clinical trials at Moffitt, you do not need a referral. Call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
-
Clinical Trials
CLINICAL TRIAL 16028
Transdisciplinary Research in Colorectal Cancer: The ColoCare Study
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 21641
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF_ Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors
Condition: Head & Neck
Intervention: BCA101 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 23309
A Platform Study of RAS(ON) Inhibitors to Treat Patients with Gastrointestinal Solid tumor - SUB-A: Study of RMC-6236 in Combination with 5-flourouracil-based regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB: Study of RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB-C: Study of RMC-6236 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma - SUB-D: Study of RMC-9805 with or without RMC-6236 in Combination with 5-flourouracil-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-E: Study of RMC-9805 with or without RMC-6236 in Combination with Cetuximab-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-F: Study of RMC-9805 With or Without RMC-6236 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with RAS G12D-Mutant Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Avastin (Bevacizumab); Bevacizumab (); CPT-11 (irinotecan); Camptosar (irinotecan); Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); RMC-6236 (); RMC-9805 (); Zoldonrasib (); eloxatin (Oxaliplatin); gemcitabine (); irinotecan (); leucovorin (); mFOLFIRINOX (); mFOLFOX6 ()
CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)